Study provides direct evidence of the role of telomeres in prostate cancer development

October 16, 2002

Boston, MA (October 16, 2002) - Telomere shortening has been proposed as an early and prevalent marker of prostate cancer process, according to a study presented today at the American Association for Cancer Research's first annual Frontiers in Cancer Prevention Research meeting. Findings of the study provide the first direct evidence that human prostate cancer may progress, in the earliest phase, via chromosomal instability generated by short telomeres, by revealing that telomere shortening is a defining DNA alteration characterizing early prostate cancer lesions.

Telomere shortening may cause significant alterations at the chromosomal level of tumors initiating chromosomal instability and causing progression to a fully malignant state. Telomeres are specialized structures located at the end of chromosomal arms that stabilize and protect chromosomes. In addition, they play a role in preventing cells from reproducing uncontrollably.

"Our study found that short telomeres may represent useful markers for assessing effectiveness in cancer chemoprevention studies," according to Alan Meeker, research fellow and lead investigator of the study which was conducted by researchers at the Brady Urological Institute and Department of Pathology, The Johns Hopkins University School of Medicine. "In addition, if telomere shortening does play a direct, causal role in the cancer process, then it represents an important prevention target in its own right."

In order to test the hypothesis that telomere shortening is an early contributor to human prostate cancer, the researchers developed and validated a new test that allows direct assessment of telomere length in clinical specimens. This study probed telomere lengths in high-grade prostatic intraepithelial neoplasia (HGPIN), the pre-invasive precursor to prostate cancer. Results showed that the telomere lengths of epithelial cells (relating to cellular tissue) within HGPIN lesions were strikingly shorter than those of adjacent normal-appearing epithelial cells in 93 percent of lesions examined.

Human tissues from prostate cancer patients, ranging from 47 to 67 years of age, were tested through microscopic examination of prostate tissue sections hybridized with a telomere-specific fluorescent peptide nucleic acid (PNA) probe. These tests revealed markedly reduced telomere signals in HGPIN lesions when compared to either the surrounding stroma (the supporting framework of an organ typically consisting of connective tissue), or to the stroma and epithelia of adjacent normal-appearing glands. Analysis of the telomere signals in a randomly-selected subset of cases revealed statistically significant telomere shortening in luminal cells (cells lining the prostatic ducts) in nine out of the 11 HGPIN lesions (82 percent) when compared to adjacent normal-appearing prostate luminal epithelial cells. The research suggests that the telomeres of PIN lesions are approximately four-fold shorter than their normal counterparts.

Perhaps most interestingly, the telomere shortening in HGPIN lesions was restricted to the luminal epithelial cells, and did not appear to occur within the basal cell compartment (at the base of the prostatic ducts, directly beneath the luminal cells). When compared to the underlying basal cell layer within the same HGPIN lesions, telomere lengths of the HGPIN luminal cells were statistically significantly shorter than the basal cells in all PIN lesions examined. Since basal cells are thought to produce secretory cells (cells that release functionally specialized secretions), it has been assumed that they are the cells that proliferate and undergo physiological transformations. However, these findings suggest that the luminal cells are not the target for potential cancerous transformation.

"We propose that telomeres are stabilized in the subset of PIN lesions that activate telomerase, and that it is these PIN lesions, theoretically capable of unlimited cell division, that may eventually progress to fully invasive cancer," said Dr. Meeker. "We are currently testing the telomere lengths in several other epithelial cancer precursor lesions to determine whether this phenomenon of early telomere shortening is widespread in other cancers."

In normal cellular activity, cells stop dividing when the telomeres shorten to a certain, pre-determined length; this action is thought to be a normal anti-tumor mechanism present in long-lived organisms. Cancer cells, however, are considered immortal; that is, they will grow indefinitely until stopped, usually by cancer treatments. Cellular immortality is believed to occur, in the majority of cancers, when the normal shortening of telomeres is counter-balanced by activation of the enzyme telomerase, which functions to maintain the lengths of telomeres. This enzyme activity has been detected in 85 percent of all cancer cells - but not in adjacent normal cells.
Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 19,000 laboratory and clinical scientists engaged in cancer research in the United States in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention).

American Association for Cancer Research

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to